Navigation Links
SyntheMed Receives Canadian Approval for REPEL-CV(R)
Date:7/14/2008

ISELIN, N.J., July 14 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged in the development and commercialization of anti-adhesion, drug delivery products and other surgical implants, announced today that REPEL-CV(R), the company's bioresorbable adhesion barrier film for the reduction of adhesions following cardiac surgery, has received Health Canada approval for use in pediatric patients who undergo open heart surgery. REPEL-CV will be marketed throughout Canada by Force3 Medicale, Inc., a Montreal-based distributor of cardiac surgery products. Marc Sportsman, SyntheMed's Vice President of Sales, stated, "We are pleased to receive the Health Canada approval which allows us to further expand the international distribution of REPEL-CV."

SyntheMed was previously granted CE Mark approval to market REPEL-CV in most international markets for use in all patients who undergo open heart surgery and is being sold through a network of independent distributors. In November 2007, SyntheMed received an Approval Letter from the US FDA stating the REPEL-CV would be approved for use in pediatric patients pending satisfactory completion of field inspections. This process is ongoing as are discussions with the FDA on the requirements for expansion of the indication for REPEL-CV from pediatric patients to all patients who undergo cardiac surgery.

About Adhesions

Adhesions, or scar tissue, occur after virtually all open-heart surgical procedures, often resulting in the heart becoming attached to the sternum and other surrounding tissue surfaces. The presence of adhesions represents a prevalent and serious complication in secondary surgical procedures, increasing the length, cost and risk of the surgical procedure.

About REPEL-CV

REPEL-CV is a bioresorbable adhesion barrier film designed to be placed over the surface of the heart at the conclusion of an open-heart surgical procedure to reduce the
'/>"/>

SOURCE SyntheMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...FOREST, Ill., Dec. 4 Hos...lty pharmaceutical and medication delivery company...n 50 mL and 100 mL VisIV(TM) containers for intrav...fers a complete size range (50 mL to 1 L) of the a...oduct. The launch of the 50 mL and 100 mL containe...
(Date:12/4/2009)..., Dec. 4 Axsun Technolog...rporation (Nasdaq: VOLC ), today announced the in...l integrated light source architecture for OCT ima...ine design raises the bar on imaging speed and ove...gns for swept source OCT light sources. This appr...
(Date:12/4/2009)...4 Drs. Neal Shore and E. David Cra...gen (PSA) recurrence from the additional analysis ...rate in a Phase III pivotal study of FIRMAGON®...prolide in prostate cancer patients during the fir...o received FIRMAGON 240/80 mg/month had a recurren...
Breaking Medicine Technology:Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Study Details Swine Flu Transmission Rates 55637 1Study Details Swine Flu Transmission Rates 55637 2Study Details Swine Flu Transmission Rates 55637 3WDIV TV Blue Cross Blue Shield of Michigan and The Parade Company Help Launch The Biggest Loser 3A Detroit Edition 55634 1WDIV TV Blue Cross Blue Shield of Michigan and The Parade Company Help Launch The Biggest Loser 3A Detroit Edition 55634 2Marine biomedicine researchers decode structure of promising sea compound 9730 1Marine biomedicine researchers decode structure of promising sea compound 9730 2
(Date:12/4/2009)...ew findings by UT Southwestern researchers suggest...rders might also help slow the destruction of insu... with insulin-dependent (type 1) diabetes. , In...tes, cells in the pancreas called beta cells, whic...process. , Researchers at UT Southwestern and 14...
(Date:12/4/2009)...ender Corp., a leading manufacturer of over-the-co...d to enhance consumers’ quality of life, tod...American Podiatric Medical Association (APMA) Seal...ealthiFeet®. , (PRWE...ufacturer of over-the-counter topical cream and fi...
(Date:12/4/2009)...IS, Dec. 4 New data from the U.S. ...ruggled to get enough to eat at some point in 2008... six Americans struggled with hunger. To wake up A...n Powell, NBC,s The Biggest Loser,s Bob Harper and...a are teaming up to turn on the production line fo...
(Date:12/4/2009)... Dec. 4 PD-Rx Pharmaceut...venue of $5,012,334 for the first quarter ended Se...iod last year. Operating income and net income fo...ely, each a 70% decrease over the same period last...n pharmacy sector sales. This trend is expected t...
(Date:12/4/2009)...-- Substantial progress has been made over the las...o diagnose and treat epilepsy and its complication...ot reached most of the 50 million people around th...n people in the United States who have the disorde...sident of the American Epilepsy Society (AES), the...
Breaking Medicine News(10 mins):Health News:FDA-approved drug may slow beta cell destruction in type 1 diabetes patients 2Health News:Tender Corp.'s HealthiFeet Awarded American Podiatric Medical Association Seal of Approval 2Health News:Tender Corp.'s HealthiFeet Awarded American Podiatric Medical Association Seal of Approval 3Health News:Tender Corp.'s HealthiFeet Awarded American Podiatric Medical Association Seal of Approval 4Health News:General Mills, NBC's The Biggest Loser and Feeding America Join Forces to Rally America to 'Wake Up to Hunger' 2Health News:General Mills, NBC's The Biggest Loser and Feeding America Join Forces to Rally America to 'Wake Up to Hunger' 3Health News:General Mills, NBC's The Biggest Loser and Feeding America Join Forces to Rally America to 'Wake Up to Hunger' 4Health News:PD-Rx Pharmaceuticals, Inc. Reports 1st Quarter Earnings 2Health News:Epilepsy patients caught in treatment gap are not getting state-of-the-art care 2Health News:Epilepsy patients caught in treatment gap are not getting state-of-the-art care 3Health News:Epilepsy patients caught in treatment gap are not getting state-of-the-art care 4
...er treatment for those living near sea level , ...s patients who call higher altitudes home may live...ording to a new study from Harvard researchers pub... a 12 percent to 15 percent lower mortality rate t...
...aschle withdrew his name for consideration as a no...artment (HHS). From the beginning Senator Daschle...sident Obama for a government takeover of our nati...Logo: http://www.newscom.com/cgi-bin/prnh/200809...
...hill.com ) today announced the start of the PRINCE...ess) study. This randomized study will determine w...Chill device during resuscitation increases patien...g for the RhinoChill system in 2007. , , The non-...
...anufacturer of,GUM(R) and Butler(R) brand products...ucts to professionals and consumers worldwide, is ...ociation,s (ADA) efforts to educate children on,th...e importance of oral health. An,estimated 4 to 5 m...
...nce most symptoms fade within 6 weeks, experts say... combination of physical therapy and anti-inflamma... back pain caused by symptomatic lumbar degenerati...appear on their own within three months and that m...
... part in regular physical activity have a better q...ry issue of the journal Cancer Epidemiology Bioma...ents who are more physically active report better ... both mentally and physically, from simple moderat...
Other Medicine News:Health News:Dialysis Patients Do Better at Higher Altitudes 2Health News:Dialysis Patients Do Better at Higher Altitudes 3Health News:BeneChill Launches European Study of Intra-Arrest Cooling 2Health News:Sunstar to Support ADA's 60th Annual National Children's Dental Health Month 2Health News:Sunstar to Support ADA's 60th Annual National Children's Dental Health Month 3Health News:Therapy, Meds Best for Lumbar Low Back Pain 2Health News:Regular physical activity linked to better quality of life in early-stage lung cancer survivors 2
COULTER AcT diff2 (Recertified)
Perclose A-T Suture-Mediated Closure
Atria 3100 ECG
...e laboratory and a worldwide leader in innovative ...n extensive test menu of highly complex and unique... Owned by the University of Utah, ARUP Laboratorie...university teaching hospitals and children's hospi...
Medicine Products: